Phase I Study of Alpelisib + Trastuzumab + LJM716 for PIK3CA-Mutated HER2+ MBC

Phase I Study of Alpelisib (Piqray) + Trastuzumab + LJM716 for PIK3CA-Mutated HER2+ Metastatic Breast Cancer

CONCLUSIONS
Combination treatment with alpelisib, trastuzumab and LJM716 was limited by gastrointestinal toxicity. Further efforts are warranted to target the PI3K pathway in HER2+ MBC.

https://www.practiceupdate.com/c/117957/67/13/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617

Unsatisfactory toxicity results limited the Novartis study.

------------------------------------------------------------------------------.

Results from our paxalisib + trastuzumab phase 2 Dana-Farber study due 2H 2021.
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Estimated Primary Completion Date : November 30, 2021.

https://clinicaltrials.gov/ct2/show/NCT03765983

Regards.